All In MedTech

Device Trial Radar · NCT02419859

A Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus

A Prospective, Single Center Study to Assess the Performance, Safety, and Patient Reported Outcomes of Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Jul 26, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

20

Actual

Start

Feb 2015

Primary completion

Nov 2015

Study completion Nov 2015

Sponsor

Lead sponsor
CeQur CorporationNot on our public-company list
Sponsor type
Industry
First posted
Apr 17, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to obtain an assessment (efficacy, safety, and patient reported outcomes) of basal bolus insulin delivery with PaQ in insulin-using patients with type 2 diabetes mellitus (T2DM).

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • PaQ® Insulin Delivery DeviceDevice

    PaQ is a 3 day insulin delivery device which delivers U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.

  • Insulin, Asp(B28)-Drug

    a fast-acting analog of human insulin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Glycosylated hemoglobin A1C (HbA1c) (obtained from venous blood)Time frame: Change from Baseline at 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical University of Graz

    Graz, Austria

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.